By vgreene, 19 March, 2020 An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19, NCT04315298
By switaschek, 19 March, 2020 If environmental risks: Reduce occupational dust/fume/gas and indoor [B]/outdoor pollutant exposure